Safety and efficacy of sintilimab versus pembrolizumab in the treatment of advanced or recurrent pediatric malignancies: a real-world study in China
Sintilimab demonstrated favorable tolerability and efficacy in pediatric patients with malignancies, with a safety and efficacy profile comparable to Pembrolizumab. For pediatric patients with advanced or recurrent malignancies receiving immune checkpoint inhibitor therapy, long-term monitoring of thyroid and cardiac function is recommended.
Authors
- Feifei Sun (ORCID: https://orcid.org/0000-0001-9539-1451)
- Mengjia Song (ORCID: https://orcid.org/0000-0002-6399-3412)
- Suying Lü (ORCID: https://orcid.org/0000-0001-8117-3533)
- Zijun Zhen (ORCID: https://orcid.org/0000-0002-4442-0897)
- Juan Wang (ORCID: https://orcid.org/0000-0002-2537-1348)
- Linnan Wu (ORCID: https://orcid.org/0009-0001-4535-3956)
- Junting Huang
- Yizhuo Zhang (ORCID: https://orcid.org/0000-0002-1529-6671)
- Mengzhen Li (ORCID: https://orcid.org/0009-0002-9775-2032)
- Lei Mao (ORCID: https://orcid.org/0009-0002-3004-7195)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-06
- DOI
- https://doi.org/10.3389/fimmu.2025.1608844
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Natural Science Foundation of Guangdong Province
- National Key Research and Development Program of China